Senate Republicans Open Investigation into Mifepristone Marketing as 340B Scrutiny Deepens
By FieldPulse Editorial · March 26, 2026
Tags: Policy, Compliance, Drug Pricing
Senate Republicans have launched a formal investigation into how mifepristone is marketed and distributed, while congressional scrutiny of the 340B drug discount program intensifies. Both carry real implications for reps in reproductive health and hospital accounts.
Two parallel legislative developments reported on March 26 are drawing attention from pharma industry observers: Senate Republicans have opened a formal investigation into the marketing and distribution practices of mifepristone manufacturers, and congressional pressure on the 340B drug discount program is continuing to build.
The mifepristone investigation adds a new layer of congressional scrutiny to a drug that has been at the center of legal and political battles since the Supreme Court's 2022 Dobbs decision.
Mifepristone, approved by the FDA for medication abortion and also used in miscarriage management, has remained on the market following a Supreme Court ruling in 2024 that dismissed a prior legal challenge on standing grounds.
But the drug has never fully exited the political crosshairs, and a formal Senate investigation into how it is marketed and distributed signals that legislative pressure is not abating.
Separately, the 340B program — which requires drug manufacturers to provide discounted medications to qualifying hospitals, federally qualified health centers, and other covered entities — has faced intensifying scrutiny on Capitol Hill.
The program has long been a source of tension between manufacturers and covered entities, with drugmakers arguing that 340B discounts are being used in ways that diverge from the program's original safety-net intent.
Congressional interest in reforming or restricting 340B has grown alongside broader legislative focus on drug pricing and hospital system economics.
For reps, both developments warrant attention depending on your call points.
Those working in reproductive health, OB/GYN practices, or specialty pharmacy networks that handle mifepristone distribution should be prepared for conversations about access, formulary status, and the regulatory environment — and should loop in their compliance and legal teams if customers raise questions that touch on political or legal risk.
Reps working hospital or IDN accounts, p.
Source: https://www.statnews.com/pharmalot/2026/03/26/fda-rare-disease-pto-novo-nordisk-340b-abortion-hiv/